332 related articles for article (PubMed ID: 24926732)
21. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
22. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
Hosp Pract (1995); 2014 Aug; 42(3):17-25. PubMed ID: 25255403
[TBL] [Abstract][Full Text] [Related]
23. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
[TBL] [Abstract][Full Text] [Related]
24. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
[TBL] [Abstract][Full Text] [Related]
25. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
Coleman CI; Antz M; Bowrin K; Evers T; Simard EP; Bonnemeier H; Cappato R
Curr Med Res Opin; 2016 Dec; 32(12):2047-2053. PubMed ID: 27633045
[TBL] [Abstract][Full Text] [Related]
26. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan.
Amin A; Keshishian A; Vo L; Zhang Q; Dina O; Patel C; Odell K; Trocio J
J Med Econ; 2018 Mar; 21(3):244-253. PubMed ID: 29047304
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.
Annavarapu S; Gandhi PK; Li Y; Arora P; Moretz C; Wang C; Sander SD; Andrews GA
J Comp Eff Res; 2018 Jul; 7(7):685-691. PubMed ID: 29808717
[TBL] [Abstract][Full Text] [Related]
29. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
Berger JS; Ashton V; Laliberté F; Germain G; Bookhart B; Lejeune D; Boudreau J; Lefebvre P; Weir MR
Adv Ther; 2023 Mar; 40(3):1224-1241. PubMed ID: 36658454
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
32. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
[TBL] [Abstract][Full Text] [Related]
33. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
[TBL] [Abstract][Full Text] [Related]
34. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
[TBL] [Abstract][Full Text] [Related]
35. Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
J Med Econ; 2021; 24(1):550-562. PubMed ID: 33910464
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
37. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25862791
[TBL] [Abstract][Full Text] [Related]
40. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
Weir MR; Ashton V; Moore KT; Shrivastava S; Peterson ED; Ammann EM
Am Heart J; 2020 May; 223():3-11. PubMed ID: 32112872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
